Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Duke University
Novartis
Information provided by (Responsible Party):
David F. McDermott, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00827359
First received: January 21, 2009
Last updated: August 29, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)